论文部分内容阅读
目的:探讨呋喃唑酮、雷贝拉唑及克拉霉素联合治疗幽门螺杆菌(Hp)胃炎的临床疗效。方法:将96例Hp感染性胃炎患者随机分为观察组与对照组,各48例。结果:观察组的治疗总有效率为97.92%,显著高于对照组的75.00%(P<0.05);观察组的Hp根除率为85.42%,显著高于对照组的66.67%(P<0.05);观察组的不良反应率为25.00%,与对照组的16.67%无明显差异(P>0.05)。结论:呋喃唑酮、雷贝拉唑及克拉霉素联合治疗Hp相关性胃炎可提高临床疗效,根除Hp,且药物副作用较少,是一种较为安全可靠的治疗方法,值得推广应用。
Objective: To investigate the clinical efficacy of furazolidone, rabeprazole and clarithromycin in the treatment of Helicobacter pylori (Hp) gastritis. Methods: 96 cases of Hp infectious gastritis were randomly divided into observation group and control group, each 48 cases. Results: The total effective rate of the observation group was 97.92%, significantly higher than that of the control group (75.00%, P <0.05). The Hp eradication rate was 85.42% in the observation group, which was significantly higher than that in the control group (66.67%, P <0.05) The rate of adverse reactions in the observation group was 25.00%, which was not significantly different from that in the control group (16.67%) (P> 0.05). Conclusion: The combination of furazolidone, rabeprazole and clarithromycin in the treatment of Hp-related gastritis can improve the clinical curative effect, eradicate Hp, and has fewer side effects. It is a safe and reliable treatment and worthy of promotion and application.